Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Synagis (palivizumab) in high-risk infants for prevention of severe RSV in the Russian Federation
2014-004527-42Phase 2
- Sponsor
- Abbott Laboratories
- Start
- Feb 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of palivizumab in respiratory syncytial virus disease (RSV), sponsored by Abbott Laboratories. Primary endpoint: Number of Hospitalizations Due to Respiratory Syncytial Virus (RSV).
02
Drugs
palivizumab
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2014-004527-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004527-42.